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Background: Wheeze and chest tightness has traditionally been associated with enhanced
bronchial responsiveness. However, no community studies are available on the associations
between bronchodilator response and respiratory symptoms among adults.
Aim: To examine how respiratory symptoms predict bronchodilator response.
Methods: An age and gender stratiﬁed random sample of all adults aged 47–48 and 71–73
years in Bergen, Norway, were invited. The 3506 participants (69%) ﬁlled in questionnaires
including nine symptoms and performed bronchodilator reversibility tests. Subjects
without current anti-asthmatic medication performing acceptable reversibility tests were
included in the analyses ðn ¼ 3088Þ.
Results: A reversibility with FEV1 increase X 12% and X 200ml was obtained in 2% of
middle-aged and 4% of elderly subjects ðp ¼ 0:001Þ. In multiple linear regression analysis
bronchodilatation was positively associated with wheezing without cold (FEV1 increase of
1.5%, 95% CI: (0.9, 2.2)% in all participants and 31ml, 95% CI: (1, 61)ml in men only) and
dyspnoea climbing two ﬂights of stairs (0.9%, 95% CI: ð0:5; 1:4Þ% and 12ml, 95% CI:
ð1; 23Þml). Chronic cough predicted the response negatively ð0:7%, 95% CI: ð1:3;0:1Þ%
and 17ml, 95% CI: ð32;2ÞmlÞ. In multiple logistic regression analysis morning cough
predicted an FEV1 increase X 12% and X 200ml (OR: 1.8, 95% CI: ð1:1; 2:8Þ).
Conclusions: A small fraction of adults in a general population has bronchodilatation after
salbutamol inhalation. ‘‘Wheezing without cold’’, ‘‘dyspnoea climbing two ﬂights of
stairs’’, and ‘‘morning cough’’ predict an increased bronchodilator response among
subjects without current anti-asthmatic medications.
& 2006 Elsevier Ltd. All rights reserved.Elsevier Ltd. All rights reserved.
of Thoracic Medicine, Haukeland University Hospital, 5021 Bergen, Norway. Tel.: +47 55 97 32 49;
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S. Lehmann et al.1184Introduction as17: the absolute response (post-salbutamol FEV1–initialAlthough asthma and chronic obstructive pulmonary disease
(COPD) are diagnosed on the basis of airﬂow variability and
limitation,1–3 a patient normally decides to seek medical
help because of unpleasant and impairing respiratory
symptoms. COPD typically presents with chronic cough,
phlegm and/or functional dyspnoea. The asthma pheno-
type has been characterised by wheezing, attacks of
dyspnoea and chest tightness. Increased bronchodilator
responsiveness is used both as a diagnostic criterion1 and
as an inclusion criterion to clinical trials on asthma.4–6
Various cut-off levels deﬁning abnormal forced expiratory
volume in one second (FEV1) responsiveness to b2-agonists
have been suggested by international respiratory societies,
such as the recent American Thoracic Society/European
Respiratory Society (ATS/ERS) criterion of 200ml and 12%
initial.7
In a recent Australian study,8 1% to nearly 5% of adults in
the community without a previous diagnosis of asthma had
positive reversibility tests. These subjects were sympto-
matic, which had considerable consequences for their
respiratory health. Nevertheless, no community-based data
is available as to what extent respiratory symptoms predict
bronchodilator responsiveness. This knowledge could sup-
port the physician’s decision on whether bronchodilator
reversibility tests should be performed based on the
patient’s symptoms.
Thus, the study objectives were to determine the
prevalence of positive bronchodilator reversibility tests
using internationally agreed cut-off values and to examine
which of the respiratory symptoms that predicts an
increased bronchodilator response among middle-aged and
elderly in a general population.
Methods
Population and measurements
An age and gender stratiﬁed random sample of 5099 subjects
were invited from two cohorts aged 47–48 years and 71–73
years living in Bergen, Norway, as part of an epidemiological
follow-up study of cardiovascular health in 1998 (the
Hordaland Health Study).9 The attendants completed
a questionnaire and performed bronchodilator reversi-
bility tests. The questionnaire elicited information on
respiratory symptoms, as well as smoking10 and current
use of anti-asthmatic medication (wording in the Appendix).
Seven questions on symptoms, Q1, Q4, Q4.1, Q4.2,
Q5–Q7, were taken from the International Union Against
Tuberculosis and Lung Disease (IUATLD) questionnaire.11,12
The two questions (Q2, Q3) from the Norwegian Respira-
tory Questionnaire have been validated against lung func-
tion and bronchial reactivity13 and compared with the
British Medical Research Council questionnaire on chronic
bronchitis.14,15
Bronchodilator reversibility tests were performed select-
ing the largest FEV1 and forced vital capacity (FVC) from any
of three acceptable and repeatable spirograms,16 before
and 15min after inhalation of 400mg salbutamol from a
Discus inhaler. The bronchodilator response was expressedFEV1)ml, and the ‘‘% initial’’ index ((post-salbutamol
FEV1–initial FEV1)/initial FEV1) 100. A positive response
was deﬁned as an FEV1 increase of X12% initial and
X200ml.7 Demographic details on the attendants, descrip-
tion of spirometry quality control procedures, and the
reversibility test performance have been published pre-
viously.18 Predicted values of FEV1 were estimated using
regression equations from a Norwegian reference popula-
tion.19 The Regional Ethics Committee has approved the
study protocol and all attendants have given a fully
informed consent to participate.Statistical analyses
Descriptive statistics based on percentages for categorical
data, means and standard deviations (SD) for quantitative
variables were used, unless otherwise stated. Univariate
analysis employed the two-sided Fisher’s test for categorical
variables and the unpaired t-test for quantitative variables.
The Mann–Whitney test was used to compare means
between groups with outcome variables deviating from
normal distribution. Multiple linear regression analysis
performed as a backward stepwise procedure was used to
evaluate the relationship between respiratory symptoms
and the bronchodilator response. Similarly, multiple logistic
regression analyses were used to examine associations
between symptoms and the ATS/ERS7 response criterion.
All regression analyses were adjusted for age-cohort,
gender, height, body mass index (BMI), smoking status
(current, ex, or never) and pack-years, and age and gender
were kept in the ﬁnal model even if not statistically
signiﬁcant. Interaction effects for pairs of symptoms, age,
and gender were estimated. A two-sided p-value less than
0.05 was considered statistically signiﬁcant. Statistical
analyses were performed using SPSS.20Results
Participation, demographics, and respiratory
symptoms
The participation rate was higher in the middle-aged (76%)
than in the elderly (64%) cohort ðp ¼ 0:0001Þ. Among the
3305 subjects who performed acceptable reversibility tests
(94% of all participants), 53% of the women and 74% of the
men were ever-smokers (Table 1).
Altogether 83% of the middle-aged and 70% of the elderly
were considered having normal lung function, the pre-
bronchodilator FEV1 in % predicted being X80% and the
FEV1/FVC ratio being X0:7. Women reported ‘‘dyspnoea
climbing two stairs’’ and ‘‘woken by chest tightness’’ more
than men did; (24% vs. 17%, p ¼ 0:001) and (9% vs. 7%,
p ¼ 0:011), respectively. Ever-smokers had a higher pre-
valence for all respiratory symptoms compared with never
smokers ðpo0:05Þ, except for ‘‘woken by chest tightness’’,
‘‘woken by attacks of breathlessness’’, and ‘‘asthma
attack’’. A total of 217 subjects (7%) were currently using
anti-asthmatic medication.
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Table 1 Prevalence (%) of participants’ basic characteristics, respiratory symptoms and current use of anti-asthmatic
medication in Bergen 1998–1999 (N ¼ 3305a).
Cohort Middle-aged Elderly p
Age 47–48 years 71–73 years
Frequency 1505 1800
Gender
Women 53 48 **
Body mass index
o20 kg=m2 4 4 **
20–24:9 kg=m2 48 37
25–29:9 kg=m2 38 46
X30 kg=m2 10 13
Smoking habitsb
Never smokers 35 38 **
Ex-smokers 29 45
Current smokers 34 15
FEV1 in % predicted
FEV1o50% 0.4 3 **
FEV1 50%–79% 20 27
FEV1X 80% 80 69
Symptoms
Q1 Morning cough 21 27 **
Q2 Chronic cough 10 11 ns
Q3 Dyspnea climbing two stairs 12 28 **
Q4 Wheezing 22 23 ns
Q4.1 Wheezing without cold 11 11 ns
Q4.2 Breathlessness when wheezing 13 12 ns
Q5 Woken with chest tightness 9 7 **
Q6 Woken by attack of breathlessness 6 6 ns
Q7 Asthma attack 3 2 ns
Current anti-asthmatic medicationc
Q12.2, 12.3, 12.4, 13.1, 14 5 8 **
aSubjects who failed the ATS 1995 spirometry quality criteria are excluded (n ¼ 201; 43 middle-aged and 158 elderly).
bMissing information on smoking habits: n ¼ 61 (2%).
cCurrent anti-asthmatic medication ¼ Answer yes to one or more of questions Q12.2, Q 12.3, Q 12.4, Q 13.1 or Q 14; i.e. long acting
b2-agonist during the last week; anticholinergics, inhaled glucocorticoids or theophylline during the last 12 months; use of b2-agonist
within the last 6 h. Differences are shown as: ns ¼ non-significant, pp0:05, pp0:01.
Respiratory symptoms predicting bronchodilator response 1185Prevalence of bronchodilator response
The frequency distribution at different cut-off points above
200ml and the average bronchodilator response in the four
age–gender groups are shown in Fig. 1. The responses were
small for both cohorts as the overall prevalence of subjects
having an FEV1 increase above 200 and 400ml was 8.3% and
0.6%, respectively. The prevalence of FEV1 increase X12%
and 200ml from initial spirometry (ATS/ERS criterion7) was
2% in the middle-aged and 5% in the elderly ðp ¼ 0:001Þ. No
responder differences were found by gender. Positive tests
were found in 86 out of 3088 subjects (2% of middle-aged
and 4% of the elderly, p ¼ 0:001) using the ATS/ERS criterion
after exclusion of people with current anti-asthmatic
medication ðn ¼ 217Þ. A total of 37 subjects (43%) of the
reversibility test positive subjects had pre-bronchodilator
FEV1/FVC ratio values below lower level of normal (LLN),using recently published Norwegian reference values21 from
the same study area.Respiratory symptoms as predictors of
bronchodilator response
Univariate analyses
Elderly subjects reporting ‘‘wheezing’’, ‘‘wheezing without
cold’’, and ‘‘asthma attack’’ and middle-aged reporting
‘‘breathless when wheezing’’ and ‘‘woken by chest tight-
ness’’ had larger bronchodilator responses than those
negative for these questions (Fig. 2).
Subjects reporting respiratory symptoms had larger
responses than asymptomatic subjects measured by the ‘‘%
initial’’ index (Fig. 3). In the elderly the response increased
gradually by the number of symptoms to a plateau at three
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Figure 1 Percentage of a community population with absolute bronchodilator response of 200–299ml, 300–399ml, 400–499ml, and
X500ml after inhalation of 400 mg salbutamol. The overall mean (SD) of bronchodilatation is given in subgroups of participating
middle-aged and elderly women and men.
S. Lehmann et al.1186reported symptoms. Among middle-aged, however, only
those reporting at least four symptoms had signiﬁcantly
larger response than the asymptomatic group (Fig. 3). No
relationship was found between number of symptoms and
bronchodilator response in either of the cohorts when using
the absolute response (ml) as outcome variable.Multivariate analyses
In multiple linear regression analyses ‘‘wheezing without
cold’’ and ‘‘dyspnoea climbing two stairs’’ predicted both
indices of bronchodilatation positively (Table 2), and the
association between ‘‘wheezing without cold’’ and the
absolute response (ml) was present in men only. ‘‘Chronic
cough’’ predicted both response indices negatively. Applying
multiple logistic regression analysis, solely ‘‘morning cough’’
was associated with a positive bronchodilator test using theATS/ERS criterion ofX12% initial andX200ml (OR: 1.8, 95%
CI: ð1:1; 2:8Þ, p ¼ 0:01).
The number of respiratory symptoms (0–7) predicted the
‘‘% initial’’ index (b ¼ 0:3, 95%CI: ð0:1; 0:4Þ, p ¼ 0:001) after
adjustment for age-cohort and gender, but was not
associated with the ‘‘absolute response’’ index in linear
analysis. Similarly in categorical analysis, the increase in
number of symptoms by one predicted the criterion ofX12%
initial and X200ml by OR: 1.2, 95% CI: ð1:0; 1:4Þ, p ¼ 0:02.Discussion
In this community study, less than 3% of middle-aged and
elderly without current anti-asthmatic medication were
classiﬁed as b2-agonist responders using the ATS/ERS
criterion (FEV1 increase of at least 200ml and 12% initial).
7
Measuring the bronchodilator response at continuous
scales, the asthma-like symptom ‘‘wheezing without cold’’
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Figure 2 Mean SE of absolute bronchodilator response (ml) after inhalation of 400 mg salbutamol by presence or absence of
respiratory symptoms. Abbreviations: ns ¼ non-significant ðp40:05Þ; pp0:05; pp0:01; pp0:001.
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Figure 3 Mean SE of FEV1 bronchodilator response (% from initial) after inhalation of 400mg salbutamol by presence of maximum
seven self-reported respiratory symptoms in middle-aged and elderly. Frequency of subjects in each symptom number category is
written below the columns. Differences in bronchodilator response are assessed by Students t-test for each symptom number
category, using the asymptomatic category as reference group; ns ¼ non-significant ðp40:05Þ; pp0:05; pp0:01:
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Table 2 Respiratory symptoms predicting the FEV1 absolute bronchodilator response (ml) and the change in % initial after
inhalation of 400 mg salbutamol in middle-aged and elderly from a general population ðN ¼ 3088Þ.
Predictors of bronchodilator response Absolute response (ml) Change in % initial
b 95% CI p b 95% CI p
Constant 77.3 ð189:8; 35:1Þ 0.18 2.3 ð2:0; 2:6Þ 0.001
Q2 Chronic cough 16.6 ð31:5;1:7Þ 0.03 0.7 ð1:3;0:1Þ 0.03
Q3 Dyspnoea climbing two stairs 11.8 (0.8, 22.8) 0.04 0.9 (0.5, 1.4) 0.001
Q4.1 Wheezing without cold 12.1 ð9:9; 34:2Þ 0.28 1.5 (0.9, 2.2) 0.001
Age (0 ¼ 47–48 years, 1 ¼ 71–73 years) 5.3 ð14:2; 3:6Þ 0.24 0.6 (0.3, 0.9 ) 0.001
Gender ð0 ¼ women; 1 ¼ menÞ 1.3 ð13:8; 11:3Þ 0.85 0.3 ð0:6; 0:02Þ 0.07
Height (cm) 0.8 (0.2, 1.5) 0.01 ns
Gender Q4:1 Wheezing without cold 31.2 (1.4, 61.0) 0.04 ns
Multivariate linear regression analysis examining nine respiratory symptoms (Appendix), age-cohort, gender, height, body mass index,
and smoking history (current, ex- or never smokers and packyears) as potential predictors of bronchodilator response. Variables with
p40:05 were removed in a backward stepwise procedure with the exception of age-cohort and gender. Interaction analyses were
performed for pairs of respiratory symptoms, age and gender, and terms with pp0:05 were introduced in a stepwise forward procedure
and kept in the model if statistically signiﬁcant.
Subjects performing an unacceptable reversibility test ðn ¼ 201Þ and subjects on current anti-asthmatic medication ðn ¼ 217Þ were
excluded from the multivariate analyses.
Abbreviations: b ¼ regression coefﬁcient; ns ¼ non-significant; CI ¼ confidence interval.
S. Lehmann et al.1188predicted the absolute response (ml) positively in men and
the ‘‘% initial’’ index in all subjects. ‘‘Dyspnoea climbing two
ﬂights of stairs’’ predicted both indices positively, while
‘‘chronic cough’’ was associated with a negative response.
‘‘Morning cough’’ was the only symptom independently
predicting the ATS/ERS criterion.7
This is the ﬁrst study assessing the relationships between
individual respiratory symptoms and the bronchodilator
response to an inhaled b2-adrenoceptor agonist measured
in adults from a general population. The strengths of the
study are a large sample and a high response rate, allowing
for precision in estimates. One well-trained technician
guided all procedures, eliminating between-operator mea-
surement variation.
The prevalence of bronchodilator response in the present
study is largely in agreement with an Australian community
study of people above 18 years.8 The overall prevalence of
achieving the reversibility criterion of X12% after inhaling
400mg salbutamol was 3.8%, compared to 4.1% in the current
study. The percentage achieving the BTS/NICE criterion of at
least 400ml,1 however, was 2.0 (SE 0.22)% in the Australian
study and 0.6 (SE 0.13)% in the current study, and the
difference is probably due to the large fraction of younger
adults in the former study.
The IUATLD respiratory symptom questionnaire, applied in
the many European Community Respiratory Health Study
(ECRHS) studies,11,22,23 has to our knowledge never been
evaluated in terms of its relation to a bronchodilator
reversibility response, but has been extensively validated
by airway hyperresponsiveness to histamine and methacho-
line.12,24 Combinations of wheezing, chest tightness, and
asthma attacks have been advocated as the asthma
syndrome.25 Bronchoconstrictor and bronchodilator respon-
siveness are, however, different phenotypic markers that
are not interchangeable.26,27 Nevertheless, we have con-ﬁrmed the association between adrenergic bronchodilator
response and ‘‘wheezing without cold’’. The relationship
between ‘‘wheezing without cold’’ and the absolute
bronchodilator response differed signiﬁcantly between
men and women, also after taking the absolute post-
bronchodilator FEV1 value (lung size) into account (results
not shown). A previous community study has shown that men
perceive respiratory symptoms at a more severe stage of
bronchoconstriction compared to women, which might
explain why men are more responsive to bronchodilators
when reporting asthma-like symptoms.28 This gender spe-
ciﬁc difference in symptom perception might be due to
higher levels of anxiety and depression in women than men
with airﬂow obstruction, as recently described in COPD
patients.29 Our data also suggest that chest wheezing
present without having a cold is a more asthma speciﬁc
question than the widely used, general question on
‘‘wheezing the last 12 months’’. This ﬁnding seems
biologically plausible. Those reporting wheezing probably
represent a mixture of subjects suffering from a variety of
conditions. Obesity causing airway narrowing,30 infections
producing oedema and mucus, congestive heart failure with
excessive interstitial ﬂuid compressing the small airways,
and obstructive lung disease with bronchial smooth muscle
constriction are all disorders resulting in turbulent, noisy
airﬂow. Thus, adding the question on wheezing excluding a
common cold eliminate those reporting the symptom solely
on the basis of simple viral airway infections.
Although to a lesser extent than ‘‘wheezing without
cold’’, ‘‘dyspnoea climbing two ﬂights of stairs’’ was
associated with an increased bronchodilator response.
Dyspnoea on exertion is a cardinal feature of obstructive
lung disease and, compared to placebo, salbutamol inhala-
tion has been shown to relieve breathlessness on exercise
both by increasing FEV1 and reducing dynamic hyperinﬂation
ARTICLE IN PRESS
Respiratory symptoms predicting bronchodilator response 1189in patients.31 Hence, the positive relationship between
functional dyspnoea and bronchodilator responsiveness in
the community was as expected.
The negative associations between chronic cough and both
response indices, however, are more difﬁcult to explain. One
might speculate that excess mucus production in the bronchi,
which covers the airway surface in subjects with chronic
cough,32 leads to an impaired access of salbutamol to the b2-
receptors on smooth muscle cells. Peribronchiolar ﬁbrosis is
also commonly seen in chronic cough,33 causing a ﬁxed
airﬂow obstruction in small airways. These ﬁndings should,
however, be conﬁrmed in future studies.
The symptoms of asthma attack and nocturnal chest
tightness did not predict the response to salbutamol.
Possibly, episodes of breathlessness caused by other diseases
like angina pectoris, heart failure, obesity, panic disorders,
and COPD may be perceived as attacks of asthma in the
Norwegian population.
Although non-predictive of bronchodilator response mea-
sured on continuous scales, morning cough was the only
symptom associated with positive test results following the
ATS/ERS7 criterion. These subjects may, at least partly,
represent a phenotype of asthmatics recognised as ‘‘cough
variant asthma’’, a clinical condition previously charac-
terised by predominance of coughing without wheezing,
normal baseline spirometry, and evidence of bronchial
hyperreactivity to methacholine challenge tests.34 This
hypothesis is supported by the fact that all 17 subjects with
morning cough and no wheeze had normal post-bronchodi-
lator FEV1/FVC ratio ð40:7Þ among those positive for the
ATS/ERS7 reversibility criterion.
Positive reversibility tests have been a prerequisite for
inclusion of subjects into a majority of clinical trials on anti-
asthmatic medications,4–6 irrespective of the pre-broncho-
dilator level of lung function. Nevertheless, the current role
of bronchodilator reversibility testing in subjects with
normal spirometry is unclear. However, a large Australian
community study8 performing bronchodilator tests in all
attendants has shown that the symptom burden is worse in
test positive (4400ml increase in FEV1)
1 than test negative
persons, even though known asthmatics were excluded.
Importantly, the mean pre-bronchodilator FEV1 in test
positive subjects was within normal limits. In an Italian
study35 of 291 asthmatics with normal baseline spirometry
25% had an FEV1 increase X12% after inhalation of 200mcg
salbutamol. Hence, data from both patient and general
populations suggest that a large fraction of cases with
reversible bronchial obstruction may be found among
subjects without demonstrable airﬂow limitation on simple
spirometry. The prognostic role of positive bronchodilator
reversibility tests in subjects with normal spirometry should
be established in future longitudinal community studies.
Our study shows that only a small fraction of middle-aged
and elderly without current anti-asthmatic treatment in the
community produce positive bronchodilator tests according to
the recently published ATS/ERS criterion. From among nine
commonly reported respiratory symptoms, positive answers to
questions on chest wheezing without having a cold, dyspnoea
climbing two ﬂights of stairs, or morning cough predict the
acute response to inhaled b2-adrenoceptor agonists. This
study provides support for including these symptom questions
when aiming to detect adults with salbutamol reversibleairﬂow obstruction. Positive answers to these questions could
also be used as one out of several indicators for b2-adrenergic
bronchodilator reversibility testing.
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Appendix
Wording of questions on respiratory symptoms and use of
anti-asthmatic medication.Q1 Do you usually cough or clear your throat in the
morning?Q2 Do you have a cough for altogether three months
or more in one year?Q3 Are you short of breath when you climb two ﬂights
of stairs at an ordinary pace?Q4 Have you had wheezing in your chest at any time
in the last 12 months?Q4.1 Have you had this wheezing without having a cold
at the same time?Q4.2 Have you been short of breath at the same time as
having this wheezing?Q5 Have you woken up at night with a feeling of
tightness in your chest at any time in the last 12
months?Q6 Have you been woken up at night by an attack of
shortness of breath at any time in the last 12
months?Q7 Have you had an attack of asthma in the last 12
months?Q12.2 Have you used inhaled long acting adrenergic
medication (Serevent, Oxis) during the last week?Q12.3 Have you used inhaled anti-cholinergic medication
(Atrovent) during the last 12 months?Q12.4 Have you used inhaled glucocorticoid (inhaled
steroids) medication (Becotide, Pulmicort,
Flutide, Flunitec) during the last 12 months?Q13.1 Have you used xanthine tablets or suppositories
(Teovent, Nuelin, Theo Dur, Euphyllin) during the
last 12 months?Q14 Have you used inhaled adrenergic medication
within the last 6 hours? (Ventoline, Bricanyl,
Berotec, Salbuvent, Serevent, Oxis).References
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